Prix 3D Medicines Inc. (01244.HK)

3D Medicines, Inc. is an investment holding company, which engages in biopharmaceutical research and development. The company is headquartered in Qingdao, Shandong and currently employs 183 full-time employees. The company went IPO on 2022-12-15. The firm focuses on the discovery, development and commercialization of innovative drugs in the field of cancer chronic disease treatment, and also lays out the field of cancer pain management. The firm has built a complete set of internal R&D systems, and has covered the entire process from drug discovery, preclinical development, clinical trials, and registration. The firm's first marketed drug, Envafolimab, is a subcutaneously injected PD-L1 inhibitor for the treatment of pan-tumor types. The firm also has a number of innovative drug research and development pipelines. The firm primarily operates in the domestic Chinese market.